Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| enterocyte | 6 studies | 39% ± 9% | |
| hepatocyte | 4 studies | 47% ± 15% |
Insufficient scRNA-seq data for expression of AADAC at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 7684.24 | 226 / 226 | 96% | 420.64 | 388 / 406 |
| pancreas | 98% | 1510.06 | 322 / 328 | 73% | 18.52 | 130 / 178 |
| adrenal gland | 100% | 16069.98 | 258 / 258 | 25% | 17.91 | 57 / 230 |
| stomach | 68% | 712.30 | 243 / 359 | 37% | 10.15 | 106 / 286 |
| lung | 44% | 149.83 | 256 / 578 | 47% | 16.75 | 541 / 1155 |
| adipose | 69% | 427.63 | 833 / 1204 | 0% | 0 | 0 / 0 |
| skin | 65% | 266.86 | 1180 / 1809 | 2% | 0.67 | 9 / 472 |
| breast | 63% | 351.17 | 289 / 459 | 3% | 1.19 | 33 / 1118 |
| ovary | 2% | 5.22 | 4 / 180 | 55% | 7.75 | 235 / 430 |
| esophagus | 11% | 16.73 | 156 / 1445 | 46% | 14.90 | 84 / 183 |
| bladder | 19% | 32.33 | 4 / 21 | 30% | 18.00 | 153 / 504 |
| intestine | 15% | 344.68 | 149 / 966 | 20% | 6.55 | 104 / 527 |
| tonsil | 0% | 0 | 0 / 0 | 16% | 3.21 | 7 / 45 |
| uterus | 2% | 3.37 | 4 / 170 | 13% | 1.47 | 58 / 459 |
| thymus | 7% | 8.76 | 46 / 653 | 0% | 0.01 | 1 / 605 |
| heart | 5% | 15.72 | 46 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 2% | 4.20 | 15 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 1% | 3.68 | 18 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 1% | 16.65 | 3 / 241 | 0% | 0 | 0 / 0 |
| kidney | 0% | 0 | 0 / 89 | 1% | 0.25 | 9 / 901 |
| prostate | 0% | 0.48 | 1 / 245 | 0% | 0 | 0 / 502 |
| brain | 0% | 0.39 | 2 / 2642 | 0% | 0 | 0 / 705 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0006629 | Biological process | lipid metabolic process |
| GO_0010898 | Biological process | positive regulation of triglyceride catabolic process |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0004806 | Molecular function | triglyceride lipase activity |
| GO_0016298 | Molecular function | lipase activity |
| GO_0017171 | Molecular function | serine hydrolase activity |
| GO_0019213 | Molecular function | deacetylase activity |
| GO_0003824 | Molecular function | catalytic activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | AADAC |
| Protein name | Arylacetamide deacetylase (EC 3.1.1.3) Arylacetamide deacetylase |
| Synonyms | DAC |
| Description | FUNCTION: Displays cellular triglyceride lipase activity in liver, increases the levels of intracellular fatty acids derived from the hydrolysis of newly formed triglyceride stores and plays a role in very low-density lipoprotein assembly. Displays serine esterase activity in liver. Deacetylates a variety of arylacetamide substrates, including xenobiotic compounds and procarcinogens, converting them to the primary arylamide compounds and increasing their toxicity. . |
| Accessions | C9K0E9 ENST00000488869.1 P22760 ENST00000232892.12 |